Reach Us +44-1904-929220
Direct Detection Of Circulating Tumor Cells (CTCs) In Blood Using Digital Cast PCR For Early Detection Of Lung Cancer | 3671

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Direct detection of circulating tumor cells (CTCs) in blood using digital cast PCR for early detection of lung cancer

2nd World Congress on Biomarkers & Clinical Research

Caifu Chen, David Deng, Fawn Wang, Yun Bao, David Merrill, and Pius Brzoska

ScientificTracks Abstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.2

E numeration and molecular characterization of circulating tumor cells (CTCs) in human blood holds great potential in cancer diagnosis, survival prognosis, and treatment guidance. However, current methods require extensive process to isolate rare CTCs in blood. We reported a new approach for direct CTC analysis in blood without cell sorting by using digital sample enrichment and reverse transcription competitive allele-specifi c TaqMan qPCR (RT-qCastPCR) for rare mutations and RT-qPCR for cancer cell-specifi c marker genes. CastPCR is capable of detecting 1 mutant in 1,000,000 wild-type molecules. Blood samples from lung cancer patients or normal individuals with spiked-in known lung cancer cell lines were partitioned in aliquots of 5 - 50 μL onto 96-well plates, such that each well contained either one cancer cell or none in the presence of 50 ? 500 thousand normal white blood cells. Genetic mutations and panel of cancer-specifi c markers including CK19 and CEA for CTC identifi cation and enumeration were determined by using both castPCR and RT-qPCR assays. Th e sample partition process resulted in a digital enrichment of 20 ? 200 folds (the relative ratio of CTC to normal cells) in a CTC- positive well. Digital castPCR accurately identifi ed known mutation and CK19 in spiked-in samples of ~10 - 60 cells per mL whole blood by two cell lines, but there was no positive well in the absence of spiked-in cells. Furthermore, cell type specifi c markers (CK19) and known EGFR mutations were identifi ed in the same sample wells, indicating that identifi ed mutation was specifi cally derived from cancer cells. In fi ve blood samples from lung cancer patients of stage I - IV, EGFR mutation (p.L858R) was detected in all samples. CTC numbers in 3 early- stage lung cancers (I and II) were 11 - 32 cells/mL blood. In contrast, > 96 CTCs/mL were detected in stage IV patients. In conclusion, our data suggest that combination of digital sample enrichment with castPCR and RT-qPCR could be used to directly enumerate CTCs and detect cancer mutations in whole blood samples of lung cancer patients
Relevant Topics